These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20811019)

  • 1. New botulinum toxin approved with REMS.
    Thompson CA
    Am J Health Syst Pharm; 2010 Sep; 67(18):1486. PubMed ID: 20811019
    [No Abstract]   [Full Text] [Related]  

  • 2. Unlabeled uses of botulinum toxins: a review, part 1.
    Cheng CM; Chen JS; Patel RP
    Am J Health Syst Pharm; 2006 Jan; 63(2):145-52. PubMed ID: 16390928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to reduce your risks when providing botulinum toxin.
    Buppert C
    Dermatol Nurs; 2008 Dec; 20(6):473-4, 492. PubMed ID: 19241745
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacology and clinical applications of botulinum toxins A and B.
    Thakker MM; Rubin PA
    Int Ophthalmol Clin; 2004; 44(3):147-63. PubMed ID: 15211183
    [No Abstract]   [Full Text] [Related]  

  • 5. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
    Wynn RL
    Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of botulinum toxin therapies.
    Madalinski MH; Slawek J
    Dis Colon Rectum; 2003 Dec; 46(12):1719-20. PubMed ID: 14668605
    [No Abstract]   [Full Text] [Related]  

  • 7. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 8. Botulinum toxin and human serum albumin.
    Malhotra R; Huilgol SC; Selva D
    Arch Ophthalmol; 2003 Nov; 121(11):1661; discussion 1661-2. PubMed ID: 14609937
    [No Abstract]   [Full Text] [Related]  

  • 9. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
    Baumann LS; Halem ML
    Arch Dermatol; 2003 Feb; 139(2):226-7. PubMed ID: 12588237
    [No Abstract]   [Full Text] [Related]  

  • 12. Botulinum toxin: does the black box warning justify change in practice?
    Narayanan UG
    Dev Med Child Neurol; 2011 Feb; 53(2):101-2. PubMed ID: 21244406
    [No Abstract]   [Full Text] [Related]  

  • 13. Botulinum toxin type B (Myobloc).
    Baumann L; Black L
    Dermatol Surg; 2003 May; 29(5):496-500; discussion 500. PubMed ID: 12752517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications, adverse reactions, and insights with the use of botulinum toxin.
    Klein AW
    Dermatol Surg; 2003 May; 29(5):549-56; discussion 556. PubMed ID: 12752527
    [No Abstract]   [Full Text] [Related]  

  • 15. Terminology for preparations of botulinum neurotoxins: what a difference a name makes.
    Albanese A
    JAMA; 2011 Jan; 305(1):89-90. PubMed ID: 21205970
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.
    Santamato A; Panza F
    Drugs; 2017 Sep; 77(13):1413-1422. PubMed ID: 28726023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B).
    U.S. Food and Drug Administration
    Plast Surg Nurs; 2008; 28(3):150-1. PubMed ID: 18794742
    [No Abstract]   [Full Text] [Related]  

  • 18. Unlabeled uses of botulinum toxins: a review, part 2.
    Cheng CM; Chen JS; Patel RP
    Am J Health Syst Pharm; 2006 Feb; 63(3):225-32. PubMed ID: 16434781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiology and pharmacology of therapeutic botulinum neurotoxins.
    Aoki KR
    Curr Probl Dermatol; 2002; 30():107-16. PubMed ID: 12471704
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.
    Rajkumar GN; Conn IG
    Urology; 2004 Jul; 64(1):2-8. PubMed ID: 15245922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.